Mangoceuticals Inc. Common Stock (MGRX)
Stock · NASDAQ · Health Care
$0.3079as of 10/16/2026
Price chart
Active signals
MGRX Signal Track Record
How signals performed across all stocks →What MGRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 24 | -2.2% | 42% | October 1, 2026 |
| Bollinger Band Breakout | 20 | -24.1% | 20% | September 16, 2026 |
| Bollinger Band BreakdownActive now | 11 | -1.2% | 45% | March 20, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -39.7% | 0% | October 6, 2026 |
| Any 20-session window (baseline) | -3.1% | 45% |
Computed by MarketWall from daily closing prices since January 4, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MGRX
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testoste…
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- Employees
- 3
- Website
- www.mangorx.com/
Fundamentals
- 1-day range
- $0.3201$0.3624
- Market cap
- $10.31M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-1.14
- Dividend yield
- —
- Beta
- 2.13
- Avg. volume
- 13.01M
How Mangoceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Apr 1, 2026 · via SEC EDGAR / Finnhub
Mangoceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MGRXMangoceuticals Inc. Common Stock$0.29▼ 9.66%Market cap $10.31MP/E —$0.162$2.75
- NIVFNewGenIvf Group Limited Class A Ordinary Shares$0.279▲ 11.60%Market cap $3.36MP/E 0.18$0.1722$24,624
- NIVFWNewGenIvf Group Limited Warrants$0.0123▼ 11.51%Market cap $102.7KP/E —$0.0086$0.09
- CCELCryo-Cell International Inc. Common Stock$4.42▲ 21.10%Market cap $28.78MP/E —$2.72$4.9
- PARKPark Dental Partners Inc. Common Stock$18.95▼ 1.33%Market cap $96.71MP/E —$9.53$26.79
- VMDViemed Healthcare Inc. Common Shares$9.48▼ 2.77%Market cap $362.60MP/E 25.72$6.05$12.61
- AGLagilon health inc. Common Stock$85.12▼ 3.76%Market cap $1.45BP/E —$7.48$133.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MGRX Mangoceuticals Inc. Common Stock | $10.31M | — | $0.29 | ▼ 9.66% | $0.162$2.75 |
| NIVF NewGenIvf Group Limited Class A Ordinary Shares | $3.36M | 0.18 | $0.279 | ▲ 11.60% | $0.1722$24,624 |
| NIVFW NewGenIvf Group Limited Warrants | $102.7K | — | $0.0123 | ▼ 11.51% | $0.0086$0.09 |
| CCEL Cryo-Cell International Inc. Common Stock | $28.78M | — | $4.42 | ▲ 21.10% | $2.72$4.9 |
| PARK Park Dental Partners Inc. Common Stock | $96.71M | — | $18.95 | ▼ 1.33% | $9.53$26.79 |
| VMD Viemed Healthcare Inc. Common Shares | $362.60M | 25.72 | $9.48 | ▼ 2.77% | $6.05$12.61 |
| AGL agilon health inc. Common Stock | $1.45B | — | $85.12 | ▼ 3.76% | $7.48$133.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Mangoceuticals Closes Registered Direct Offering Following $2.5M Strategic Investment Commitment In MangoRx IP Holdings To Support Intellectual Property Commercializationbenzinga · 10/9/2026
- Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market CloseYahoo · 10/9/2026
- Mangoceuticals Closes Registered Direct Offering Following $2.5M Strategic Investment Commitment In MangoRx IP Holdings To Support Intellectual Property CommercializationBenzinga · 10/9/2026
- Curious about the stocks that are showing activity after the closing bell on Tuesday?ChartMill · 10/6/2026
- Stock Market Today: S&P 500, Dow Jones Futures Gain as September Jobs Report Misses Expectations— Nike, Synaptics, Corteva in Focus (UPDATED)Benzinga · 10/2/2026
- Nike Posts Mixed Q1 Results, Joins Mangoceuticals And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · 10/2/2026
- Nike, Synaptics And 3 Stocks To Watch Heading Into FridayBenzinga · 10/2/2026
- Mangoceuticals (MGRX) Shares Fall 12% After Hours: Here's WhyBenzinga · 10/2/2026
- What's going on in today's after hours sessionChartMill · 10/1/2026
Insider Activity
Insider Actions →- Cohen Jacob D. · August 11, 2026 · Gift2.00M
- Alex P. Hamilton · July 28, 2026 · Grant100.0K
- Cohen Jacob D. · July 28, 2026 · Grant2.00M
- JOHNSTON EUGENE M · July 28, 2026 · Grant100.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 769.3K
- Total value held
- $255.1K
- Institutional holders
- 17
- Unknown194.5K
- Unknown138.1K
- Unknown123.0K
- Unknown72.7K
- Unknown61.0K
- Unknown38.4K
- Unknown37.6K
- Unknown34.5K
- Unknown16.0K
- Unknown13.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
MGRX Shares Drop 12% After Hours Amid $2.5M Investment Announcement
Mangoceuticals shares fell 12% in after‑hours trading after the company announced a $2.5 million investment in its MangoRx IP. The deal provides an initial $1.75 million tranche and additional funding from strategic investors. Despite the funding, the market reacted negatively, pulling the stock lower. The move highlights the volatility around the company’s valuation.
MGRX Shares Drop 12% After Hours Amid $2.5M Investment Announcement. Mangoceuticals shares fell 12% in after‑hours trading after the company announced a $2.5 million investment in its MangoRx IP. The deal provides an initial $1.75 million tranche and additional funding from strategic investors. Despite the funding, the market reacted negatively, pulling the stock lower. The move highlights the volatility around the company’s valuation.